Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 23.06.16 in Vol 5, No 2 (2016): Apr-Jun

This paper is in the following e-collection/theme issue:

Works citing "Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial"

Juliana N. Anyanwu, Olatundun Williams, Casey L. Sautter, Phillip Kasirye, Heather Hume, Robert O. Opoka, Teresa Latham, Christopher Ndugwa, Russell E. Ware, Chandy C. John

JMIR Res Protoc 2016 (Jun 23); 5(2):e110 

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.5599):

(note that this is only a small subset of citations)

  1. Carman AS, Sautter C, Anyanwu JN, Ssemata AS, Opoka RO, Ware RE, Rujumba J, John CC. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood & Cancer 2020;67(2)
    CrossRef
  2. Power-Hays A, Ware RE. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Current Opinion in Hematology 2020;27(3):172
    CrossRef
  3. Green NS, Munube D, Bangirana P, Buluma LR, Kebirungi B, Opoka R, Mupere E, Kasirye P, Kiguli S, Birabwa A, Kawooya MS, Lubowa SK, Sekibira R, Kayongo E, Hume H, Elkind M, Peng W, Li G, Rosano C, LaRussa P, Minja FJ, Boehme A, Idro R. Burden of neurological and neurocognitive impairment in pediatric sickle cell anemia in Uganda (BRAIN SAFE): a cross-sectional study. BMC Pediatrics 2019;19(1)
    CrossRef
  4. Smart LR, Hernandez AG, Ware RE. Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations. Seminars in Hematology 2018;55(2):102
    CrossRef
  5. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. The Lancet 2017;390(10091):311
    CrossRef
  6. Epting CL, Emmer BT, Du NY, Taylor JM, Makanji MY, Olson CL, Engman DM, Weiss LM, Docampo R, Tanowitz H. Cell Cycle Inhibition To Treat Sleeping Sickness. mBio 2017;8(5)
    CrossRef
  7. McGann PT, Hernandez AG, Ware RE. Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. Blood 2017;129(2):155
    CrossRef
  8. Opoka RO, Ndugwa CM, Latham TS, Lane A, Hume HA, Kasirye P, Hodges JS, Ware RE, John CC. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood 2017;130(24):2585
    CrossRef
  9. Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews 2017;2017(4)
    CrossRef
  10. John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. New England Journal of Medicine 2020;382(26):2524
    CrossRef
  11. Nartey EB, Spector J, Adu-Afarwuah S, Jones CL, Jackson A, Ohemeng A, Shah R, Koryo-Dabrah A, Kuma AB, Hyacinth HI, Steiner-Asiedu M. Nutritional perspectives on sickle cell disease in Africa: a systematic review. BMC Nutrition 2021;7(1)
    CrossRef
  12. Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews 2022;2022(10)
    CrossRef
  13. Esoh K, Wonkam-Tingang E, Wonkam A. Sickle cell disease in sub-Saharan Africa: transferable strategies for prevention and care. The Lancet Haematology 2021;8(10):e744
    CrossRef
  14. Dexter D, McGann PT. Hydroxyurea for children with sickle cell disease in sub‐Saharan Africa: A summary of the evidence, opportunities, and challenges. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2023;43(5):430
    CrossRef
  15. Awor S, Bongomin F, Kaggwa M, Pebalo F, Musoke D. Prevalence of Use of Herbal Medicines for the Treatment of Sickle Cell Disease in Africa: a Systematic Review and Meta-analysis. Journal of Herbal Medicine 2023;42:100735
    CrossRef
  16. Santos B, Ginete C, Gonçalves E, Delgadinho M, Miranda A, Faustino P, Arez AP, Brito M. Characterization of a cohort of Angolan children with sickle cell anemia treated with hydroxyurea. Blood Cells, Molecules, and Diseases 2024;105:102822
    CrossRef
  17. Drown L, Osei M, Thapa A, Boudreaux C, Archer N, Bukhman G, Adler AJ. Models of care for sickle cell disease in low-income and lower-middle-income countries: a scoping review. The Lancet Haematology 2024;11(4):e299
    CrossRef
  18. Siegert TF, Opoka RO, Nakafeero M, Carman A, Mellencamp KA, Latham T, Hume H, Lane A, Ware RE, Ssenkusu JM, John CC, Conroy AL. Angiopoietin-2 is associated with sickle cell complications, including stroke risk, and decreases with hydroxyurea therapy. Blood Vessels, Thrombosis & Hemostasis 2024;1(1):100001
    CrossRef

According to Crossref, the following books are citing this article (DOI 10.2196/resprot.5599):

  1. Anderson CL, Darbari DS. Sickle Cell Disease and Hematopoietic Stem Cell Transplantation. 2018. Chapter 3:65
    CrossRef